Literature DB >> 25403224

When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?

Nai-Kong V Cheung1, Shakeel Modak1, Irina Ostrovnaya1, Stephen S Roberts1, Ellen M Basu1, Kim Kramer1, Brian H Kushner2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25403224     DOI： 10.1200/JCO.2014.58.1678

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Frank Berthold
Journal:  Cochrane Database Syst Rev       Date:  2017-08-25

2.  Reply to N.-K.V. Cheung et al.

Authors:  Katherine K Matthay; Wendy B London; John Maris; Peter C Adamson; Julie R Park
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

3.  Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.

Authors:  C Pasqualini; C Dufour; G Goma; M-A Raquin; V Lapierre; D Valteau-Couanet
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

4.  Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

Authors:  Frank Berthold; Angela Ernst; Barbara Hero; Thomas Klingebiel; Bernhard Kremens; Freimut H Schilling; Thorsten Simon
Journal:  Br J Cancer       Date:  2018-07-11       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.